Quitting weight-loss drugs or a diet can cause weight regain—two strategies could help prevent
Millions of people are now turning to GLP-1 weight-loss medications like Wegovy and Zepbound to lose weight and improve their health. These medications have transformed obesity treatment and helped many people achieve significant weight loss.
But there’s one major concern researchers are trying to solve:
What happens after people stop taking these drugs?
Unfortunately, many individuals regain a large portion of the weight they lost once treatment ends. The same challenge is often seen after traditional dieting. However, two new clinical studies published in Nature Medicine suggest there may finally be practical ways to maintain weight loss even after quitting GLP-1 medications.
Why Weight Regain Happens After GLP-1 Drugs
GLP-1 medications work by helping people feel full longer, reducing appetite, and improving blood sugar control. While these drugs are highly effective, obesity experts increasingly believe weight management is a long-term process rather than a short-term fix.
When people stop taking the medication, appetite often returns, cravings increase, and the body may naturally try to regain lost weight. This biological response makes long-term maintenance difficult.
According to recent estimates, nearly one in eight American adults now use GLP-1 drugs for diabetes management or weight loss. Because many users eventually stop treatment due to cost, side effects, or personal preference, researchers are urgently looking for ways to prevent rebound weight gain.
Study 1: Oral GLP-1 Pill May Help Maintain Weight Loss
The first study focused on an oral GLP-1 drug called orforglipron, recently approved under the brand name Foundayo.
Researchers followed more than 370 participants who had already lost weight using injectable medications such as:
- Ozempic
- Wegovy
- Mounjaro
- Zepbound
After 72 weeks on injections, participants switched either to a daily orforglipron pill or to a placebo.
Key Findings
People who switched to the oral GLP-1 pill maintained far more of their weight loss than those who stopped treatment completely.
Researchers found participants retained:
- About 79% of weight loss after semaglutide treatment
- About 75% of weight loss after tirzepatide treatment
Meanwhile, the placebo group regained significantly more weight.
This suggests that transitioning from weekly injections to a daily tablet could become a practical long-term strategy for weight maintenance.
Why This Matters
Many people dislike injections or struggle with the long-term expense of injectable medications. A daily oral pill may offer a more convenient and acceptable option for ongoing weight management.
Experts believe this flexibility could improve long-term adherence and help people sustain healthier lifestyles.
However, researchers also caution that oral GLP-1 medications are still relatively new. Long-term safety and effectiveness data remain limited compared to older injectable treatments.
Study 2: Gut Bacteria Supplement Shows Modest Benefits
The second study explored a completely different approach involving gut health.
Researchers investigated a supplement containing a pasteurized form of Akkermansia muciniphila, a beneficial gut bacterium linked to metabolism and weight regulation.
In the trial, 84 adults first completed an eight-week low-calorie diet. They were then randomly assigned either:
- The bacterial supplement
- Or a placebo
Both groups followed a balanced diet afterward.
What Researchers Discovered
After six months, participants taking the supplement regained less weight overall and maintained approximately three kilograms more total weight loss than the placebo group.
Although the results were considered modest, researchers say they are encouraging because they highlight the growing role of gut microbiome science in obesity treatment.
Could Gut Health Become the Future of Weight Maintenance?
Scientists increasingly believe the gut microbiome may play a major role in metabolism, hunger, inflammation, and fat storage.
The bacteria Akkermansia muciniphila has already shown promising results in earlier animal studies and smaller human trials. This latest research strengthens the possibility that targeted microbial therapies may eventually support long-term weight management.
Future studies are expected to explore:
- Longer-term effects
- Personalized gut microbiome treatments
- Combination therapies with GLP-1 drugs
- Natural bacterial levels in individuals
Featured Snippet: How Can People Prevent Weight Regain After Stopping GLP-1 Drugs?
Two emerging strategies may help prevent weight regain after stopping GLP-1 medications:
- Switching from injectable GLP-1 drugs to an oral medication like orforglipron
- Using gut-health supplements containing Akkermansia muciniphila bacteria
Early studies show both approaches may help maintain weight loss, although more long-term research is still needed.
The Bigger Picture in Obesity Treatment
These studies reinforce an important reality: obesity is a chronic condition that often requires ongoing management.
For many people, successful long-term weight control may eventually involve a combination of:
- Medication
- Nutrition
- Exercise
- Gut microbiome support
- Behavioral changes
- Long-term medical supervision
Researchers are optimistic that future therapies will become more personalized, effective, and easier to maintain over time.
As GLP-1 medications continue reshaping modern healthcare, the next major breakthrough may not simply be losing weight — but keeping it off permanently.
#WeightLoss #GLP1 #Wegovy #GutHealth #ObesityTreatment